Investment research report for LH

Table of Contents

Executive Summary
Valuation Analysis
Industry and Competitors Analysis
Financial Analysis
Earnings Call Multi-Year Analysis
Financial Statements Multi Year
Insider Trading Analysis
Management Compensation Benchmark Analysis
Proxy Statement Analysis
News Analysis
Technical Indicators Analysis
Financial Statements Annual
Financial Statements Quarterly
Earnings Call Analysis

Executive Summary

Company Description

Laboratory Corporation of America Holdings (LH) is a leading global life sciences company that operates in two main segments: Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The Dx segment provides diagnostic testing services, including routine and esoteric testing, to healthcare providers, hospitals, and patients. The BLS segment offers drug development and clinical trial testing services to pharmaceutical and biotechnology companies. LH has a strong presence in the United States and operates in several international markets.

Financial Performance

LH has demonstrated consistent revenue growth, driven by organic growth, strategic acquisitions, and favorable currency impacts. However, profitability metrics like gross profit margin, operating margin, and net income margin have faced pressure due to factors like the decline in higher-margin COVID-19 testing, higher personnel costs, and impacts from acquisitions/divestitures. The company has maintained a strong liquidity position with substantial cash reserves and available credit facilities.

Strategic Initiatives

LH has undertaken several strategic initiatives to drive long-term growth and shareholder value. These include the spin-off of its Fortrea business, the planned spin-off of its Clinical Development and Commercialization Services (CDCS) business, and the LaunchPad business transformation initiative to drive operational focus and cost savings. The company has also been actively deploying capital through acquisitions, share repurchases, and consistent dividend payments.

Challenges and Opportunities

LH faces various legal proceedings and investigations related to data security, labor practices, and alleged privacy violations, which could potentially impact its financial performance and reputation. The company also has significant underfunded pension and retirement plan obligations, which require ongoing contributions and could impact future cash flows. However, LH’s diversified offerings, strategic initiatives, and strong financial position provide opportunities for long-term growth and value creation.

Back to Table of Contents

Valuation Analysis

PE ratio

  • Low: 1.734551259478648
  • Base: 17.489921370641632
  • High: 33.245291481804614

PB ratio

  • Low: 1.597496049139115
  • Base: 2.033163857640437
  • High: 2.468831666141759

FCF Growth

  • Low: -16.89%
  • Med: 1.78%
  • High: 8.34%

Value forecast by FCF

  • Low: 50.49
  • Med: 122.20
  • High: 178.93

The price of LH today is $203.81.

Price target for 18 months from now

  • Low: 180.81
  • Med: 191.57
  • High: 200.08

Price target for 4 years from now

  • Low: 142.48
  • Med: 171.17
  • High: 193.86

Price target for 10 years from now

  • Low: 50.49
  • Med: 122.20
  • High: 178.93

The net present value multiplier discounted at 10.32% gives the value of the stock as:
– Low: 0.25
– Med: 0.60
– High: 0.88

The upside/downside ratio is 0.19, and our rating is Strong Sell.

Back to Table of Contents

Industry and Competitors Analysis

Revenue and Market Capitalization

LH has a larger revenue ($12.16 billion in 2023) and market capitalization ($16.43 billion) compared to DGX ($9.25 billion revenue and $15.77 billion market cap), indicating a larger scale of operations.

Profitability

LH’s profitability ratios (gross profit, EBITDA, operating income, and net income) are generally lower than DGX’s in recent years, suggesting that DGX may have a slight edge in terms of profitability.

Diversification

LH operates in two segments (Labcorp Diagnostics and Labcorp Drug Development), while DGX seems to be more focused on diagnostic testing services. This diversification could provide LH with a broader range of offerings and revenue streams.

Industry Presence

Both LH and DGX have a significant presence in the medical diagnostics and research industry, serving various customers, including healthcare providers, pharmaceutical companies, and government agencies.

Overall, LH appears to be a major player in the medical diagnostics and research industry, with a slightly larger scale of operations compared to its closest competitor, DGX. However, DGX seems to have a slight edge in terms of profitability ratios in recent years. The competitive positioning between these two companies is likely to be closely contested.

Back to Table of Contents

Chart of Competitors

"Chart of Competitors"

Back to Table of Contents

Financial Analysis

Financial Strength

The company has maintained a relatively stable return on equity and return on assets over the past few years, indicating decent profitability. The current ratio is around 1-2, suggesting adequate liquidity to cover short-term obligations. The debt-to-equity ratio is moderate, ranging from 0.5 to 1, which is reasonable for the industry.

Potential for Growth

Revenue growth has been inconsistent, with some quarters showing declines and others showing modest growth. The company’s 3-year revenue growth per share has been negative in recent quarters, which could be a concern for future growth. Analyst estimates suggest moderate revenue growth expectations of around 3-5% annually over the next few years.

Competitive Advantage

As a leading life sciences company, LH likely benefits from its scale, brand recognition, and diversified service offerings. However, the industry is competitive, and the company’s growth rates do not suggest a significant competitive edge over peers.

Quality of Management

The company has maintained a relatively stable financial position, which could be seen as a sign of decent management. However, the inconsistent revenue growth and lack of significant competitive advantages may raise questions about management’s ability to drive long-term growth.

Shareholder Friendliness

LH has paid dividends in recent years, although the dividend yield is relatively low. The payout ratio has fluctuated but has generally been below 50%, leaving room for reinvestment in the business. Share buybacks have not been a significant part of the company’s capital allocation strategy.

Valuation

The price-to-earnings ratio has varied significantly but has generally been in the range of 10-20, which could be considered reasonable for the industry. The price-to-book ratio has also been relatively stable, around 1.5-2.5, suggesting that the company is not significantly over or undervalued based on its book value.

Overall, Laboratory Corporation of America Holdings appears to be a financially stable company with decent profitability and a moderate growth outlook. While it may not have a significant competitive advantage, its diversified offerings and scale could provide some resilience. The company’s shareholder friendliness is average, with a focus on reinvesting in the business. Valuation metrics suggest that the stock is reasonably valued based on its current financial performance.

Back to Table of Contents

Chart of Key Per Share Metrics

"Chart of Key Per Share Metrics"

Back to Table of Contents

Chart of Absolute Metrics

"Chart of Absolute Metrics"

Back to Table of Contents

Earnings Call Multi-Year Analysis

Strong base business performance

LabCorp’s core diagnostics and drug development businesses are showing consistent organic growth, even excluding the impact of COVID-19 testing. This suggests a solid foundation for future growth.

Strategic acquisitions and partnerships

The company is actively pursuing acquisitions and partnerships, particularly in areas like oncology testing, hospital/health system relationships, and decentralized clinical trials. These initiatives position LabCorp for long-term growth in attractive markets.

Cost management and productivity initiatives

LabCorp is focused on driving operational efficiencies and cost savings through programs like LaunchPad to offset inflationary pressures and maintain profitability.

Balanced capital allocation

The company is committed to deploying capital towards strategic acquisitions, share repurchases, and dividends, reflecting a disciplined approach to enhancing shareholder value.

Diversified business model

LabCorp’s presence across diagnostics and drug development services provides diversification and exposure to multiple growth opportunities.

Cautious outlook on COVID-19 testing

While COVID-19 testing has been a tailwind, the company remains cautious about the sustainability of these volumes and is focused on managing the impact on its core businesses.

Transparency and strategic focus

LabCorp’s management team appears transparent in its communication, providing detailed segment-level information and addressing analyst concerns. The company also seems focused on strategic initiatives to unlock long-term value.

Overall, the key insights suggest that LabCorp has a solid foundation, a clear strategic direction, and a disciplined approach to capital allocation – factors that should position the company well for long-term growth and value creation, despite near-term challenges.

Back to Table of Contents

Financial Statements Multi Year

Revenue Growth and Diversification

The company has demonstrated consistent revenue growth, driven by organic growth, acquisitions, and favorable currency impacts. It operates in two main segments – Diagnostics (Dx) and Biopharma Laboratory Services (BLS/Drug Development), providing diversification.

While revenue has grown, profitability metrics like gross profit margin, operating margin, and net income margin have faced pressure due to factors like the decline in higher-margin COVID-19 testing, higher personnel costs, and impacts from acquisitions/divestitures.

Cash Flow and Liquidity Position

The company has maintained a strong liquidity position with substantial cash reserves and available credit facilities. However, operating cash flows have declined recently due to lower cash earnings.

Capital Allocation

The company has been actively deploying capital through acquisitions, share repurchases, and consistent dividend payments, demonstrating a commitment to returning value to shareholders.

Strategic Moves

The company has undertaken strategic initiatives like the spin-off of its Fortrea business, the planned spin-off of its Clinical Development and Commercialization Services (CDCS) business, and the LaunchPad business transformation initiative to drive operational focus and cost savings.

The company faces various legal proceedings and investigations related to data security, labor practices, and alleged privacy violations, which could potentially impact its financial performance and reputation.

Pension and Retirement Obligations

The company has significant underfunded pension and retirement plan obligations, which require ongoing contributions and could impact future cash flows.

Overall, while the company has demonstrated revenue growth and strategic initiatives, profitability pressures, legal challenges, and pension obligations are areas that warrant close monitoring by long-term investors.

Back to Table of Contents

Insider Trading Analysis

Long-term Patterns

The CEO, Adam H. Schechter, and the CFO, Glenn A. Eisenberg, have been consistently granted and exercising large amounts of stock options and restricted stock units over the past few years. This indicates they have significant equity-based compensation and are incentivized to drive long-term shareholder value.

Other key executives like Brian J. Caveney, Mark S. Schroeder, and Sandra D. van der Vaart have also been granted and exercising similar equity awards, suggesting a broad-based equity compensation program across the senior leadership team.

There have been several large open-market purchases by directors like Kerrii B. Anderson and Jean-Luc Belingard, which could signal their confidence in the company’s long-term prospects.

Recent Transactions

In the most recent transactions, the CEO, CFO, and other executives have been actively exercising stock options and vesting of restricted stock units, often selling a portion of the shares acquired.

The sale transactions appear to be for diversification and liquidity purposes rather than any major concerns about the company’s outlook.

The continued granting of new equity awards to the leadership team suggests the company is committed to aligning their interests with shareholders through long-term incentives.

Implications

The insider trading activity indicates that the company’s senior leadership team has significant equity stakes and is incentivized to drive long-term shareholder value.

The mix of option exercises, restricted stock vesting, and open-market purchases suggests a balanced approach to managing their equity positions.

Overall, the insider trading patterns do not raise any major red flags and appear consistent with typical equity compensation practices for a company of this size and stature.

Back to Table of Contents

Management Compensation Benchmark Analysis

Executive Compensation Insights

Based on the executive compensation details provided for LH, the key insights are:

  1. The average percentage of base salary out of total compensation for the executives at LH is 18.688360105017143%. This is lower than the average for executives at DGX (18.478342565349003%) and WAT (29.989450283171397%), but higher than the average for executives at UHS (33.534269295301435%) and HUM (24.185627386527855%).

  2. The CEO of LH, Adam H. Schechter, had a base salary that was only 8.596667387388289% of his total compensation in 2023. This is significantly lower than the base salary percentages for the CEOs of DGX (6.780839595836986% in 2018), WAT (7.804313705849318% in 2018), UHS (7.5589362808997755% in 2017), and HUM (6.436327444763835% in 2017).

  3. Other LH executives like the Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer (16.27450391398611% in 2023) and the Executive Vice President and Chief Financial Officer (16.249712262625494% in 2023) had higher base salary percentages compared to the CEO, but still lower than the industry averages.

Overall, the executive compensation at LH appears to be more heavily weighted towards variable, performance-based compensation (stock awards and incentive plan compensation) rather than fixed base salary, compared to the peer companies analyzed. This suggests the compensation structure may be more aligned with creating long-term shareholder value, as the executives’ payouts are more closely tied to the company’s financial and stock performance.

Back to Table of Contents

Proxy Statement Analysis

Evaluation of Executive Compensation

The following analysis is based on the latest proxy statement of LH:

Based on the information provided in the proxy statement, I do not have enough confidence to make a definitive assessment about whether Labcorp’s executive compensation is well-aligned with creating long-term shareholder value. The proxy statement raises valid concerns around Labcorp’s data privacy practices and potential risks related to reproductive healthcare data, but it does not provide specific details about the company’s executive compensation structure or metrics.

To properly evaluate the alignment of incentives, I would need more information from Labcorp’s public filings and disclosures, such as:

  1. Details on the specific performance metrics and weightings used in the executive compensation plans, and how they incentivize long-term value creation.

  2. Information on whether data privacy, cybersecurity, and related risks are explicitly incorporated into the executive compensation plans, and if so, how they are weighted and measured.

  3. Disclosure on the level of transparency and stakeholder engagement around data privacy practices, and whether executives are incentivized to improve in these areas.

  4. An understanding of how Labcorp’s compensation practices compare to industry peers and best practices in terms of aligning pay with long-term performance and risk management.

Without more specific information from the company itself, it is difficult to confidently assess the degree to which Labcorp’s executive compensation drives long-term value creation while appropriately managing the data privacy risks highlighted in the proxy statement. As a long-term investor, I would seek out additional disclosures from Labcorp to make a more informed evaluation.

Back to Table of Contents

News Analysis

Positive Factors

LH continues to launch new testing services and products related to COVID-19, monkeypox, Alzheimer’s etc. which can drive revenue growth. Strategic alliances and acquisitions to expand capabilities in areas like oncology testing, clinical trials etc. Strong base business growth and demand for routine testing services. Beat earnings estimates in recent quarters aided by COVID testing volumes.

Potential Concerns

Decline in COVID-19 testing volumes and sales as the pandemic subsides can impact revenues. Margin pressures due to higher costs. Macroeconomic headwinds and currency woes impacting performance. Planned spin-off of drug development business (Fortrea) could create uncertainty.

Overall, LH seems well-positioned to benefit from new testing opportunities and portfolio expansions. However, investors need to watch for normalization of COVID-19 testing demand and the impact of the planned Fortrea spin-off. Continued earnings growth, new product launches and strategic initiatives could provide long-term tailwinds if executed effectively.

Back to Table of Contents

Technical Indicators Analysis

Next Week Trading

The recent price action and technical indicators suggest a potential short-term consolidation or pullback in the next week. The 10-day RSI is in the neutral range around 50, indicating the stock is not overbought or oversold in the near-term. The 20-day TEMA is also flattening out, hinting at a potential pause in the upward momentum. Traders may look for opportunities to take profits or enter short-term positions on any pullbacks towards support levels.

Resistance and Support Levels

The 20-day, 50-day, and 200-day SMAs provide key support and resistance levels to monitor. The stock is currently trading above all three moving averages, suggesting a bullish trend. The 200-day SMA around $210.69 could act as a support level, while the 50-day SMA around $202.06 may provide resistance in the short-term.

Short-Term Investor

The recent price action and technical indicators paint a mixed picture for short-term investors. The 10-day RSI is in the neutral range, indicating the stock is not overbought or oversold in the near-term. However, the flattening 20-day TEMA suggests the upward momentum may be slowing. Short-term investors may consider taking profits or adopting a more cautious approach in the coming week, looking for opportunities to re-enter on any pullbacks towards support levels.

Long-Term Investor

For long-term investors, the overall technical picture remains positive. The stock is trading above the 20-day, 50-day, and 200-day SMAs, indicating a bullish trend. The 200-day SMA around $210.69 provides a solid long-term support level. As long as the stock maintains above this level, the long-term uptrend remains intact. Long-term investors may consider holding their positions or looking for opportunities to add to their positions on any significant pullbacks.

Back to Table of Contents

Chart of Valuation History

"Chart of Valuation History"

Back to Table of Contents

Financial Statements Annual

Financial Statements Annual 2024 Q2

Financial Performance

Revenue grew 2.5% year-over-year to $12.16 billion in 2023. Gross profit margin was 25.9%, down from 27.1% in the prior year. Operating income declined 49.5% to $1.12 billion, with the operating margin decreasing from 12.1% to 9.2%. Net income decreased 29.1% to $418 million, with net margin declining from 4.6% to 3.4%. Earnings per share (diluted) were $4.77, down from $5.41 in the prior year.

Balance Sheet and Cash Flows

Cash and cash equivalents increased from $320.6 million to $536.8 million. Total assets were $16.73 billion, with $9.48 billion in goodwill and intangible assets. Total debt was $5.95 billion, resulting in a net debt position of $5.42 billion. Free cash flow generation remained strong at $874.1 million.

The company is facing several lawsuits and investigations related to data security incidents, accessibility issues, labor practices, and alleged privacy violations. The company has settled or reached preliminary settlement agreements for some of the labor-related lawsuits. The company is vigorously defending itself against the remaining legal proceedings.

Pension and Retirement Plans

The company sponsors defined benefit pension plans in the U.S. and internationally, which are underfunded by $268 million. The company expects to contribute $168 million to the pension plans in 2024. The company also sponsors a postretirement medical plan with a $36 million benefit obligation.

Overall, the financial performance declined year-over-year, with lower profitability and margins. The company is facing various legal challenges, but has been able to settle some of the labor-related lawsuits. The pension and retirement plans remain an area of focus, with the company needing to make significant contributions to the underfunded plans.

Financial Statements Annual 2023 Q2

Strong Financial Performance

LH reported solid financial results in 2022, with revenue of $14.88 billion, gross profit of $4.39 billion, and net income of $1.28 billion. This demonstrates the company’s ability to generate consistent profitability.

Efficient Operations

LH’s operating margin of 11.92% and EBITDA margin of 18.44% indicate the company’s ability to manage costs and operate efficiently, which is important for long-term sustainability.

Healthy Balance Sheet

LH has a strong balance sheet, with $430 million in cash and cash equivalents and a manageable debt load of $6.29 billion. This provides financial flexibility to invest in growth initiatives or weather any economic downturns.

Pension Plan Obligations

LH has defined benefit pension plans, which are underfunded by $327 million for the U.S. plans and $207 million for the non-U.S. plans. This represents a potential liability that the company will need to address over time, potentially impacting future cash flows.

LH is involved in various legal proceedings, including a lawsuit related to unfair competition and subpoenas from government agencies regarding urine drug testing and non-invasive prenatal screening tests. While the company is cooperating with these investigations, the potential financial impact and outcome of these legal matters are uncertain.

Pension and Postretirement Plan Costs

LH’s defined benefit pension and postretirement plans contribute to its operating expenses, with net periodic benefit costs of $77 million for the U.S. plans and $55 million for the non-U.S. plans in 2022. These costs may fluctuate based on changes in actuarial assumptions and investment performance.

Diversified Revenue Streams

LH operates two main business segments, Diagnostics (Dx) and Drug Development (DD), which provide some diversification and balance to the company’s revenue sources.

Overall, LH appears to be a financially stable and well-managed company, with strong operational performance and a healthy balance sheet. However, the company’s pension obligations and ongoing legal matters warrant close monitoring by long-term investors.

Financial Statements Annual 2022 Q2

Strong financial performance in 2021

Revenue grew 15.4% to $16.12 billion, driven by the Diagnostics (Dx) segment. Gross profit margin was 34.9%, indicating solid profitability. Operating income increased 33.2% to $3.26 billion, with an operating margin of 20.2%. Net income grew 24.1% to $2.38 billion, with a net margin of 14.7%. Earnings per share (diluted) was $24.38, up from $20.88 in 2020.

Strong cash flow generation

Net cash provided by operating activities was $3.11 billion. Free cash flow (operating cash flow less capital expenditures) was $2.65 billion, indicating the company’s ability to generate substantial cash.

Disciplined capital allocation

The company repurchased $1.67 billion of common stock, demonstrating a commitment to returning capital to shareholders. Debt levels remained manageable, with net debt (total debt less cash and short-term investments) of $4.87 billion.

Pension plan management

The company maintains defined benefit pension plans, which are sensitive to changes in discount rates and expected returns on plan assets. A 1 percentage point change in the discount rate or expected return on plan assets can have a significant impact on pension expense. The company evaluates and updates assumptions periodically to reflect actual experience and expectations.

Acquisition and strategic initiatives

In February 2022, the company announced a strategic collaboration with Ascension, a large healthcare system, to manage their hospital-based laboratories and acquire certain outreach laboratory assets. Also in February 2022, the company acquired Personal Genome Diagnostics, a cancer genomics company, to expand its oncology portfolio and liquid biopsy capabilities.

Overall, the financial statements demonstrate Laboratory Corporation of America’s strong operational and financial performance, disciplined capital allocation, and strategic initiatives to drive long-term growth and shareholder value.

Back to Table of Contents

Financial Statements Quarterly

Financial Statements Quarterly 2024 Q2

Revenue Growth

The company saw strong revenue growth of 4.6% in Q1 2024 compared to Q1 2023, driven by 2.3% organic growth, 1.8% from acquisitions, and 0.5% from favorable foreign currency translation. This indicates the company is executing well on its growth strategy.

Segment Performance

  • The Diagnostics (Dx) segment saw a 4.1% revenue increase, with 1.8% organic growth and 2.2% from acquisitions. However, Dx operating margin declined 170 basis points due to a reduction in COVID-19 testing, adverse weather, and the mix impact from lab management agreements.
  • The Biopharma Laboratory Services (BLS) segment saw a strong 7.5% revenue increase, driven by 5.1% organic growth and 2.4% from favorable foreign currency. BLS operating margin improved 290 basis points due to organic growth and cost savings.

Profitability

Gross profit margin remained relatively stable at 72.0% in Q1 2024 compared to 72.0% in Q1 2023. However, selling, general and administrative expenses increased as a percentage of revenue, from 15.1% to 16.0%, primarily due to higher personnel costs and lower COVID-19 testing revenue.

Cash Flow and Liquidity

Operating cash flow from continuing operations decreased from $1,857 million in Q1 2023 to $(298) million in Q1 2024, primarily due to lower cash earnings and timing of working capital requirements. The company had $993 million in cash and $9,576 million in available borrowings under its revolving credit facility as of March 31, 2024, providing ample liquidity.

Acquisitions and Capital Allocation

The company made several acquisitions during Q1 2024 totaling $2,592 million, indicating its continued focus on inorganic growth. The company also paid $621 million in dividends during the quarter and had $5,315 million remaining under its share repurchase authorization as of March 31, 2024.

Overall, the financial statements demonstrate the company’s ability to drive revenue growth, both organically and through acquisitions, while managing costs and maintaining a strong liquidity position. However, the decline in Dx operating margin and the decrease in operating cash flow are areas that warrant close monitoring by long-term investors.

Financial Statements Quarterly 2024 Q1

Separation of Fortrea Holdings

Labcorp completed the spin-off of Fortrea Holdings on June 30, 2023, distributing 100% of Fortrea’s shares to Labcorp shareholders. The spin-off is expected to be tax-free for Labcorp and its shareholders. However, the separation may pose risks and challenges that could impact Labcorp’s business, including failure to achieve intended benefits, potential exposure to unexpected liabilities, and disruptions to customer/supplier relationships. Labcorp’s ability to engage in certain capital-raising or strategic transactions may be limited to preserve the tax-free status of the spin-off.

Financial Performance

Revenues increased 2.2% year-over-year for the nine months ended September 30, 2023, driven by acquisitions and organic growth, partially offset by a decline in COVID-19 testing. Gross profit margin declined from 32.6% to 27.9% due to the reduction in higher-margin COVID-19 testing and the impact of the Ascension lab management agreement. Operating income decreased 39.7% year-over-year, primarily due to the decline in COVID-19 testing, higher corporate expenses related to the spin-off, and increased amortization and restructuring costs. The company remains on track to deliver approximately $350 million in net savings from its three-year LaunchPad initiative by the end of 2024.

Liquidity and Capital Allocation

The company had $7.28 billion in cash and $9.1 billion in available borrowing capacity under its revolving credit facility as of September 30, 2023. Labcorp used $10 billion of the proceeds from the Fortrea spin-off to fund an accelerated share repurchase program, with the remaining funds to be used for debt repayment and future shareholder returns. The company paid $1.93 billion in dividends during the first nine months of 2023 and announced a $0.72 per share dividend for the fourth quarter. Labcorp remains committed to maintaining its investment-grade credit ratings and leverage ratio covenants.

Overall, the key insights center around the successful completion of the Fortrea spin-off, the financial and operational challenges faced due to the decline in COVID-19 testing, and Labcorp’s focus on cost savings, capital allocation, and maintaining a strong balance sheet to navigate the transition.

Financial Statements Quarterly 2023 Q4

Separation of Fortrea Holdings

On June 30, 2023, Labcorp completed the separation of its Fortrea business segment through a pro-rata distribution of Fortrea shares to Labcorp shareholders. The spinoff is expected to be tax-free and provides Labcorp an opportunity to focus on its core Diagnostics and Biopharma Laboratory Services businesses. The separation resulted in Labcorp receiving approximately $16 billion in cash, which it plans to use for an accelerated $10 billion share repurchase program, paying down $3 billion in debt, and returning the remaining funds to shareholders through future share repurchases and/or dividends.

Financial Performance

Revenues for the six months ended June 30, 2023 were $60.7 billion, a 0.1% increase compared to the prior year period. The increase was driven by 1.6% growth from acquisitions, offset by a 1.3% decline in organic revenue and 0.2% unfavorable foreign currency impact. The organic revenue decline was primarily due to a 11.2% decrease in COVID-19 testing, partially offset by a 9.9% increase in the base business. Gross profit margin decreased from 66.6% to 72.1% due to the decline in higher-margin COVID-19 testing revenue, higher personnel costs, and the impact of the Ascension lab management agreement. Operating income decreased 42.4% to $6.0 billion, with the Diagnostics segment operating margin declining 740 basis points to 18.0% and the Biopharma Laboratory Services segment operating margin declining 60 basis points to 13.1%. The decline in operating income and margins was primarily driven by the reduction in COVID-19 testing revenue and higher personnel costs, partially offset by growth in the base business.

Capital Allocation and Liquidity

Labcorp has $19.3 billion in cash and cash equivalents and $10 billion available under its revolving credit facility as of June 30, 2023. The company plans to use $10 billion of the Fortrea spinoff proceeds for an accelerated share repurchase program and $3 billion to pay down debt maturing this year. Labcorp paid $1.29 billion in dividends during the first half of 2023 and announced a $0.72 per share dividend for the third quarter of 2023. The company remains committed to maintaining its investment-grade credit ratings and expects to remain in compliance with its debt covenants over the next 12 months.

Overall, the separation of Fortrea provides Labcorp an opportunity to focus on its core diagnostics and biopharma services businesses. While the company faces headwinds from the decline in COVID-19 testing revenue, the strong performance of the base business and planned capital allocation actions, including the accelerated share repurchase program, should be positive for long-term shareholders.

Financial Statements Quarterly 2023 Q3

Total revenues decreased 3.1% year-over-year, driven by a 3.6% decline in organic revenue, partially offset by 1.2% from acquisitions. Diagnostics (Dx) segment revenues decreased 2.9%, with a 4.7% decline in organic revenue partially offset by 2.0% from acquisitions. Drug Development (DD) segment revenues decreased 4.0%, primarily due to a 2.4% organic decline, 1.5% unfavorable foreign currency impact, and 0.1% from divestitures.

Profitability

Gross profit margin decreased from 31.6% to 25.8%, primarily due to lower COVID-19 testing revenue and higher personnel costs. Operating income margin decreased from 17.6% to 9.0%, driven by the decline in gross margin, higher selling, general and administrative expenses, and increased amortization of intangibles. Net earnings margin decreased from 12.6% to 5.6%, reflecting the lower operating performance.

Cash Flows and Liquidity

Operating cash flow decreased from $3,560 million to $1,212 million, primarily due to lower cash earnings. The company had $3,939 million in cash and cash equivalents and $10,000 million available under its revolving credit facility as of March 31, 2023. The company paid $644 million in dividends during the quarter and announced a $0.72 per share dividend for the second quarter of 2023.

Planned Spinoff of CDCS Business

The company announced plans to spin off its Clinical Development and Commercialization Services (CDCS) business, which includes parts of the DD segment, into a separate publicly traded company. The spinoff is expected to provide strategic flexibility, operational focus, and tailored capital structures for the two independent companies.

Operational Challenges

The DD segment faced headwinds from non-human primate supply constraints, reduced COVID-19 vaccine and therapeutic work, and the loss of a functional services provider contract. The company continues to invest in its LaunchPad business transformation initiative, which is expected to deliver $3,500 million in net savings by the end of 2024.

Overall, the financial statements indicate a challenging operating environment, with the company navigating the decline in COVID-19 testing revenue and operational challenges in the DD segment. The planned spinoff of the CDCS business represents a strategic move to unlock value and position the two companies for focused growth. Long-term investors may want to closely monitor the company’s ability to drive profitability in the core Dx business and the successful execution of the CDCS spinoff.

Back to Table of Contents

Earnings Call Analysis

Earnings Call Analysis 2024 Q2

Strategic Acquisitions and Partnerships

LabCorp is making strategic acquisitions to strengthen its specialty testing capabilities, particularly in oncology and rare diseases. The acquisition of select Invitae assets is expected to accelerate LabCorp’s growth in these important therapeutic areas.

LabCorp is focused on driving growth through partnerships with health systems and regional/local laboratories, as well as launching new tests in key areas like neurodegenerative diseases and oncology. This suggests the company is positioning itself as a partner of choice in the industry.

Diagnostics Segment Performance

The company’s Diagnostics segment is performing well, with strong volume and price/mix growth. However, margins in this segment have been impacted by lower COVID-19 testing, weather, and the integration of lab management agreements. Investors should monitor how LabCorp manages these margin dynamics going forward.

Biopharma Laboratory Services Segment

The Biopharma Laboratory Services segment has seen strength in the Central Labs business, offsetting some softness in the Early Development business due to higher-than-normal cancellations. Investors should watch for signs of improvement in the Early Development business as the year progresses.

Operational Efficiency Initiatives

LabCorp is focused on driving operational efficiency through its LaunchPad initiatives, which are expected to deliver $100-$125 million in savings this year. This suggests the company is proactively managing costs to maintain profitability.

Guidance and Capital Allocation

The company’s guidance reflects confidence in its ability to deliver continued profitable growth and strong free cash flow, which it plans to use for strategic acquisitions and returning capital to shareholders.

Overall, LabCorp appears to be executing well on its strategic priorities, though investors should monitor the integration of recent acquisitions, the dynamics in the Diagnostics segment, and the recovery in the Early Development business within Biopharma.

Earnings Call Analysis 2024 Q1

Momentum in the core diagnostics business

The company is seeing strong growth in its base diagnostics business, driven by focus areas like oncology, women’s health, autoimmune disease, and neurology. This suggests sustainable organic growth potential.

Successful integration of hospital and regional lab partnerships

The company has been able to successfully integrate new hospital and regional lab partnerships, which are accretive in the first year and expand margins over time. This inorganic growth strategy appears to be working well.

Margin improvement expected

Despite headwinds from lower COVID testing, the company expects margin expansion in both the diagnostics and biopharma segments in 2024, driven by cost savings initiatives, volume growth, and improved integration of recent acquisitions.

Robust biopharma business

The biopharma lab services segment continues to perform well, with strength in the central lab business offsetting some softness in early development. The company is optimistic about the long-term outlook for this segment.

Cautious on regulatory environment

The company remains concerned about potential PAMA cuts and is actively advocating for the SALSA legislation to avoid reimbursement pressure. This regulatory risk should be monitored.

Disciplined capital allocation

The company plans to deploy its strong free cash flow generation towards accretive acquisitions, share repurchases, and dividends – a balanced approach that should benefit long-term shareholders.

Overall, the company appears to be executing well on its strategic priorities and positioning itself for continued growth and margin expansion, though regulatory risks should be closely watched.

Earnings Call Analysis 2023 Q4

Diagnostics Laboratories Segment

The diagnostics business is performing well, with the base business growing 12.8% organically in Q3. This indicates strong underlying demand. The Ascension lab management agreement is contributing significantly to the growth, around 6% of the organic growth. Managed care contracting is in a good position, with contracts being renewed at flat to slightly positive rates. Routine testing growth is consistent, while esoteric testing is growing slightly faster.

Biopharma Laboratory Services Segment

The central lab business remains strong, with 9% growth in Q3. The early development business has seen higher than normal cancellations and lower orders, primarily due to small biotech funding challenges. The company is looking to shift the early development business more towards mid-sized biotech and pharma companies, rather than relying too much on smaller emerging biotech. The book-to-bill ratio was below 1 in Q3 for the early development business, but the company expects it to improve in Q4.

Strategic Initiatives

The company is focused on two key growth drivers: being the partner of choice for health systems and local/regional labs, and developing, licensing, and scaling specialty testing including companion diagnostics. The company has announced several new health system partnerships in the Northeast and West Coast, which are expected to be accretive in the first year and return the cost of capital within three years. The company is investing in innovative testing, such as the new ATN profile for Alzheimer’s disease assessment and a consumer offering for menopause testing.

Financial Outlook

The company has provided long-term guidance of 5-8% enterprise revenue growth, including 1.5-2.5% from acquisitions. Diagnostics Laboratories are expected to grow organically 2.5-4.5%, and Biopharma Laboratory Services 4.5-7.5%. The company expects to face a headwind of around 70 basis points in 2024 due to the impact of lower COVID testing and the PAMA reimbursement changes. The company is targeting 100-150 basis points of margin improvement over the 2023-2026 period, with most of the improvement coming after 2024.

Overall, the company appears to be executing well on its strategic initiatives, with strong performance in the diagnostics business and a focus on high-growth areas like specialty testing. The Biopharma segment faces some near-term challenges, but the company is taking steps to address them. The long-term financial outlook seems promising, though the impact of PAMA reimbursement changes in 2024 will need to be closely monitored.

Earnings Call Analysis 2023 Q3

LabCorp’s Base Business Performing Well

LabCorp’s base business is performing very well, with the Diagnostics Laboratories segment growing 16% year-over-year in the quarter. This strong base business growth offsets the decline in COVID-19 testing revenue.

Biopharma Laboratory Services Segment Outlook

The Biopharma Laboratory Services segment is expected to see improved growth in the second half of the year, as the supply constraints in the Early Development Research Laboratories business are resolved. The Central Laboratories business continues to see strong volume growth.

Expanding Hospital and Health System Partnerships

LabCorp is focused on expanding its hospital and health system partnerships, which provide immediate value but have lower margins initially that improve over time. The Ascension partnership integration is going well.

Investing in Innovation and Technology

LabCorp is investing in innovation and technology, such as new liquid biopsy and Alzheimer’s tests, to support diagnostic and drug development testing across disease areas.

Cost Optimization Initiatives

The company is taking actions to remove $25 million in annualized stranded costs from the spin-off of Fortrea, in addition to the $350 million in LaunchPad savings it is targeting over 3 years.

Acquisition Pipeline and Growth Opportunities

LabCorp maintains a robust pipeline of potential hospital and local laboratory acquisitions, which it sees as an important growth opportunity.

Capital Allocation Priorities

The company is focused on using its free cash flow for acquisitions, share repurchases and dividends to drive shareholder value.

Overall, the key insights point to LabCorp’s strong base business performance, strategic initiatives to drive growth, and financial discipline, which should position the company well for long-term success.

Earnings Call Analysis 2023 Q2

Diagnostics Business Performance

The diagnostics business is performing very well, with the base business revenue growing 10% in Q1 excluding COVID testing. This strong performance has led the company to increase its full-year guidance for the Diagnostics segment.

Drug Development Segment Challenges

The Drug Development segment faced some challenges in Q1 due to NHP supply constraints, reduced COVID-related work, and the loss of an FSP contract. However, the company expects these issues to improve in the second half of 2023.

Planned Spin-off of Clinical Development Business

The planned spin-off of the Clinical Development business is on track for mid-year completion. The company believes this will create two strong independent companies and allow for increased focus on their respective businesses.

M&A Opportunities in Diagnostics

The company is actively pursuing M&A opportunities, particularly in the diagnostics business, with a robust pipeline of potential health system and local lab acquisitions. This suggests the company is focused on inorganic growth.

Short-term Challenges in Drug Development Segment

Analyst questions imply some short-term customer delays and a slower backlog burn rate in the Drug Development segment as customers wait for the spin-off to be completed before awarding new business. However, the company remains confident in the long-term prospects of this business.

Cost Controls and Margin Expansion Initiatives

The company is focused on cost controls and margin expansion initiatives, such as the LaunchPad program, to offset inflationary pressures and maintain profitability.

Overall, the company appears to be executing well on its strategic initiatives, with a strong diagnostics business and a plan to unlock value through the spin-off of the Clinical Development segment. The long-term investor should closely monitor the company’s progress on the spin-off, the performance of the Diagnostics and Drug Development segments, and the company’s ability to navigate the current challenges in the CRO business.

Earnings Call Analysis 2023 Q1

Diversified business model

LabCorp operates in two main segments – Diagnostics and Drug Development. This diversification helps mitigate risks and provides growth opportunities across different areas.

Strong base business growth

Excluding COVID-19 testing, LabCorp’s base business revenue grew 6% in Q4 and is expected to grow 8.5-10.5% in 2023, benefiting from partnerships like Ascension.

Planned spin-off of Clinical Development

LabCorp plans to spin off its Clinical Development business into a separate public company called Fortrea. This will allow the two businesses to better focus on their respective strategies and customer needs.

Continued M&A and partnerships

LabCorp has an active pipeline of hospital and local laboratory acquisitions and partnerships, which will be a key growth driver going forward.

Cautious on COVID-19 testing outlook

LabCorp expects COVID-19 testing revenue to decline 75-90% in 2023, reflecting the uncertainty around the pandemic’s trajectory.

Margin pressure and cost management

LabCorp faces margin pressure from lower COVID-19 testing, inflationary costs, and the impact of the Ascension partnership. The company is focused on cost savings through its LaunchPad initiatives.

Capital allocation priorities

LabCorp plans to use its free cash flow for acquisitions, share repurchases, and dividends, reflecting its commitment to shareholder returns.

Overall, the call suggests LabCorp is navigating a challenging environment well, with a diversified business model, strong base business growth, and strategic initiatives to drive long-term value creation.

Earnings Call Analysis 2022 Q4

Diagnostics Business Fundamentals Remain Strong

The diagnostics business fundamentals remain strong, with the base business growing 3-4% expected for the full year. The Ascension partnership is a significant growth opportunity, though it will be dilutive to margins initially as the integration is prioritized.

Drug Development Business Facing Temporary Headwinds

The Drug Development business is facing some temporary headwinds – lower COVID-related work, the Ukraine-Russia crisis, and labor shortages impacting the early development segment. However, the underlying demand and backlog remain healthy, and management expects these issues to be temporary.

Cost Control and Margin Improvement Initiatives

The company is focused on cost control and margin improvement initiatives through the LaunchPad program to offset inflationary pressures across both segments.

Cautious 2023 Guidance

Management is cautious about providing 2023 guidance, but sees opportunities for continued growth in the base business, while acknowledging headwinds from lower COVID testing volumes and potential PAMA reimbursement changes.

Planned Spin-off of Clinical Development Business

The planned spin-off of the Clinical Development business is progressing, with the goal of completing it by mid-2023. This is expected to provide enhanced strategic flexibility and focus for both the remaining Labcorp business and the new standalone entity.

Capital Deployment Demonstrates Confidence

The company continues to deploy capital towards acquisitions, share buybacks and dividends, demonstrating confidence in the long-term prospects of the business.

Overall, the discussion suggests Labcorp has strong fundamentals, but is navigating some near-term operational challenges. The long-term investor should focus on the company’s ability to manage costs, drive organic growth, and successfully execute the planned spin-off to unlock shareholder value.

Earnings Call Analysis 2022 Q3

Spin-off of Clinical Development Business

Labcorp is pursuing a spin-off of its clinical development business to create two independent, global public companies. The spin-off will provide greater strategic flexibility, operational focus, and tailored capital structures for each business to innovate, grow, and enhance shareholder value. The clinical development business will retain access to Labcorp’s health and clinical data through an arrangement to support its customers.

Diagnostics Business

The Diagnostics business has shown strong underlying performance, with the base business revenue growing 3.9% year-over-year and 4.3% CAGR from 2019 to 2022. Margins in the Diagnostics business were impacted by the decline in COVID-19 testing revenue and a shift in payer mix, but the company expects base business margins to improve in the second half of the year.

Drug Development Business

The Drug Development business experienced flat revenue growth in the quarter, with growth in early development and clinical development offset by a decline in central labs. Margins in the Drug Development business improved to 14.7% in the quarter and are expected to continue increasing throughout the year. The company expects the Drug Development business to deliver high single-digit revenue growth going forward.

Acquisitions and Partnerships

Labcorp continues to pursue acquisitions and partnerships to supplement its organic growth, including the acquisition of select outreach business assets from Prisma Health, AtlantiCare, and RWJBarnabas Health. The company also announced a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color.

Analyst Questions

Analysts probed for more details on the margin profiles of the clinical development business compared to the other segments, as well as the impact of recent acquisitions on margins. The company acknowledged that the clinical development business has historically had higher margins but is impacted by pass-through revenues, and that recent acquisitions have had a dilutive impact on margins, which the company expects to be temporary.

Overall, the key insights suggest that Labcorp is taking strategic actions to position its businesses for long-term growth and value creation, while maintaining a strong financial position and commitment to capital allocation. The company appears to be transparent in its communication and responsive to analyst questions, providing a critical perspective for long-term investors.

Earnings Call Analysis 2022 Q2

The company’s base business (excluding COVID-19 testing) continues to show strong performance

The company’s base business (excluding COVID-19 testing) continues to show strong performance, with Diagnostics base business revenue growing 5.6% and Drug Development base business revenue growing 3.3% (4.5% on a constant currency basis) in Q1 2022 compared to Q1 2021.

The company is focused on high-growth opportunities

The company is focused on high-growth opportunities, including strategic acquisitions and partnerships with healthcare systems. Recent examples include the acquisition of PGDx to enhance oncology capabilities and partnerships with Prisma Health, AtlantiCare, and Ascension.

The company is facing some near-term headwinds

The company is facing some near-term headwinds, including lower COVID-19 testing volumes, inflationary pressures on personnel and other costs, and impacts from the conflict in Ukraine. However, the company expects these headwinds to ease over the course of 2022.

The company provided detailed segment-level information on its Drug Development business

The company provided detailed segment-level information on its Drug Development business, showing varying performance across the early development, clinical trial testing solutions, and clinical development and commercialization services units. This level of transparency is positive.

The company initiated a quarterly dividend

The company initiated a quarterly dividend, which signals confidence in its long-term cash flow generation and commitment to shareholder returns.

Overall, the company appears to be executing well on its strategic priorities, though near-term challenges remain. The detailed disclosures and focus on high-growth opportunities are positive signs for long-term investors.

Earnings Call Analysis 2022 Q1

Strong Base Business with Organic Growth

LabCorp has a strong base business with organic growth in both Diagnostics (3.5-6%) and Drug Development (7.5-10%) expected in 2022. This suggests a solid underlying business beyond the COVID-19 testing tailwinds.

Focus on Profitable Growth

The company is focused on profitable growth, with plans to deliver $350 million in cost savings over the next 3 years through its LaunchPad initiative to offset inflationary pressures on labor and supplies.

Strategic Investments and Acquisitions

LabCorp is making strategic investments and acquisitions to expand its capabilities, particularly in oncology diagnostics and decentralized clinical trials. The PGDx acquisition and Ascension partnership are examples of this.

Commitment to Shareholder Value

Management is committed to enhancing shareholder value, with the initiation of a dividend, a $2.5 billion share repurchase program, and a long-term outlook for 11-14% adjusted EPS CAGR from 2019 levels.

Analyst Skepticism and Execution Challenges

The analysts’ questions suggest some skepticism around the sustainability of COVID-19 testing volumes and the ability to offset inflationary pressures. LabCorp will need to demonstrate its ability to execute on its cost savings and growth initiatives.

Overall, LabCorp appears to be positioning itself for long-term success by investing in its base business, expanding its capabilities, and returning capital to shareholders. However, the company will need to navigate near-term headwinds and continue to execute on its strategic priorities.

Earnings Call Analysis 2021 Q4

The base business for both the Diagnostics and Drug Development segments is rebounding well and showing consistent recovery. This provides a strong foundation for the company’s future growth.

The company is maintaining higher headcount levels to be prepared for potential future COVID-19 scenarios, which is leading to higher labor costs. However, the company is focused on finding efficiencies and reducing costs where possible to offset these pressures.

The company has a robust M&A pipeline, with opportunities in both diagnostic laboratory acquisitions as well as strategic acquisitions to enhance capabilities in key growth areas like digital health and decentralized clinical trials. This suggests the company is actively pursuing inorganic growth.

The company is conducting a thorough strategic review to ensure it is best positioned to unlock shareholder value. While details have not been provided, the company seems committed to finding ways to get better credit for the value of its businesses.

The impact of COVID-19 testing volumes remains a key variable going forward. The company plans to provide a range of possibilities for COVID-19 testing in its 2022 guidance, in addition to the outlook for the base business.

The company is embracing telehealth and virtual care models, suggesting it is adapting to evolving healthcare trends and maintaining strong relationships with key industry players.

Overall, the company appears to be executing well on its core business while also proactively managing the challenges posed by the pandemic and positioning itself for long-term growth through strategic initiatives and M&A.

Earnings Call Analysis 2021 Q3

Strong performance across both the Diagnostics and Drug Development segments

Diagnostics base business revenue and volume have recovered to pre-COVID levels, with June 2021 volume exceeding June 2019 levels. The Drug Development segment saw strong double-digit growth across all areas, with a robust book-to-bill ratio of 1.41.

Cautious optimism on COVID-19 testing outlook

COVID-19 testing revenue was flat year-over-year, but the company has narrowed its guidance range to a 33-38% decline, reflecting the impact of the Delta variant and the extended public health emergency. The company is prepared to handle potential increases in COVID-19 testing, including for back-to-school programs, but has not seen significant commitments from schools yet.

Ongoing focus on cost management and productivity improvements

The company is facing labor cost pressures but expects to offset these through its ongoing “Launchpad” initiatives, which aim to drive productivity and efficiency. The company is also exploring opportunities to expand margins in the Drug Development segment as it moves forward.

Robust M&A pipeline and capital allocation strategy

The company continues to actively pursue strategic acquisitions, particularly in the oncology and hospital/laboratory spaces. The company has a strong balance sheet and plans to deploy its free cash flow towards M&A and share repurchases in the second half of the year.

Cautious tone on long-term guidance

The company has maintained a wide guidance range for 2021, reflecting the ongoing uncertainty in the operating environment. Analysts probed for more details on the 2022 outlook, but the company indicated it is still focused on executing its 2021 plan before providing guidance for the next year.

Overall, the key insights suggest that Laboratory Corporation of America is well-positioned to navigate the current environment, with a focus on driving growth in its core businesses, managing costs, and deploying capital strategically. However, the company remains cautious about the long-term outlook due to the ongoing COVID-19 pandemic and its potential impact on testing volumes and pricing.

Back to Table of Contents

The information provided on this blog is for informational purposes only and should not be considered as financial advice. You should consult with a qualified financial professional before making any investment decisions. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal.